NFIA-ETO2融合蛋白阻断红系成熟并与突变型TP53协同诱导纯红系白血病
研究在鼠红系母细胞中表达NFIA-ETO2融合蛋白,发现其显著增加增殖并损害红系分化,但单独表达不足以在移植后致病;与TP53R248Q突变共存时则产生异常克隆形成活性并在小鼠中诱导完全外显的可移植PEL样疾病。分子机制上NFIA-ETO2通过优先结合并抑制含NFI结合位点和/或ETO2修饰的红系基因,使靶基因活性从GATA基序向ETS基序转移,而TP53R248Q不影响红系分化但通过下调TP53靶基因提供自我更新和生存潜能。
要点
- NFIA-ETO2单独表达可增加鼠红系母细胞增殖并损害红系分化,但无异常克隆形成和移植致病能力。
- NFIA-ETO2与TP53R248Q共存时诱导异常克隆形成活性及完全外显的可移植PEL样疾病。
- NFIA-ETO2通过结合抑制含NFI位点和/或ETO2修饰的红系基因,使靶基因活性从GATA基序向ETS基序转移。
核心结论
- NFIA-ETO2通过抑制终末红系分化基因表达程序启动PEL,并与TP53突变协同诱导红系白血病。
研究设计与样本
- 在鼠红系母细胞(EBs)中表达NFIA-ETO2融合蛋白,并在有无TP53R248Q突变条件下进行体外克隆形成及移植实验。
主要发现
- NFIA-ETO2显著增加鼠红白血病细胞和原代胎肝来源EBs的增殖并损害红系分化。
- 表达NFIA-ETO2的EBs在体外无异常克隆形成活性,移植入经照射的同系小鼠后无致病潜能。
- 在TP53R248Q存在下,NFIA-ETO2表达导致异常克隆形成活性,并在小鼠中诱导完全外显的可移植PEL样疾病。
- NFIA-ETO2优先结合并抑制含NFI结合位点和/或ETO2修饰的红系基因,导致靶基因活性从GATA基序向ETS基序转移。
- TP53R248Q不影响红系分化,但主要通过下调已知TP53靶基因提供自我更新和生存潜能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The NFIA-ETO2 fusion is the product of a t(1;16)(p31;q24) chromosomal translocation, so far, exclusively found in pediatric patients with pure erythroid leukemia (PEL). To address the role for the pathogenesis of the disease, we facilitated the expression of the NFIA-ETO2 fusion in murine erythroblasts (EBs). We observed that NFIA-ETO2 significantly increased proliferation and impaired erythroid differentiation of murine erythroleukemia cells and of primary fetal liver-derived EBs. However, NFIA-ETO2-expressing EBs acquired neither aberrant in vitro clonogenic activity nor disease-inducing potential upon transplantation into irradiated syngenic mice. In contrast, in the presence of 1 of the most prevalent erythroleukemia-associated mutations, TP53R248Q, expression of NFIA-ETO2 resulted in aberrant clonogenic activity and induced a fully penetrant transplantable PEL-like disease in mice. Molecular studies support that NFIA-ETO2 interferes with erythroid differentiation by preferentially binding and repressing erythroid genes that contain NFI binding sites and/or are decorated by ETO2, resulting in a activity shift from GATA- to ETS-motif-containing target genes. In contrast, TP53R248Q does not affect erythroid differentiation but provides self-renewal and survival potential, mostly via downregulation of known TP53 targets. Collectively, our work indicates that NFIA-ETO2 initiates PEL by suppressing gene expression programs of terminal erythroid differentiation and cooperates with TP53 mutation to induce erythroleukemia.
引用
- Piqué-Borràs MR, Jevtic Z, Bagger FO, et al. The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53. Blood. 2023. PMID: 36735909. doi:10.1182/blood.2022017273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。